Cytotoxicity, apoptosis, cellular uptake, cell cycle arrest, photocleavage, and antioxidant activity of 1, 10-phenanthroline ruthenium(II) complexes.

Two new ruthenium(II) complexes, [Ru(phen)2(DNPIP)](ClO4)2 (1) and [Ru(phen)2(DAPIP)](ClO4)2 (2), were synthesized and characterized. The DNA-binding properties of these complexes were investigated using UV/vis absorption titration, viscosity measurements, thermal denaturation, and photoactivated cleavage. The DNA binding constants for complexes 1 and 2 are 2.63 ± 0.25×10(5) M(-1) (s=2.45) and 1.51±0.18×10(5) M(-1) (s=1.34). The results indicated that these complexes interacted with DNA through the intercalative mode. The cytotoxicity in vitro of complexes 1 and 2 were assessed against BEL-7402, HepG-2, and MCF-7 cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was studied with the acridine orange/ethidium bromide staining method. The antiproliferative mechanism was explored with flow cytometry. Cellular uptake studies showed that complexes 1 and 2 can enter into the cytoplasm and accumulate in the nuclei. Cell cycle arrest and antioxidant activity were also investigated.

[1]  Guanying Li,et al.  Synthesis, DNA-binding and topoisomerase inhibitory activity of ruthenium(II) polypyridyl complexes. , 2011, European journal of medicinal chemistry.

[2]  Jun-hua Yao,et al.  Synthesis of ruthenium(II) complexes and characterization of their cytotoxicity in vitro, apoptosis, DNA-binding and antioxidant activity. , 2010, European journal of medicinal chemistry.

[3]  Jun-hua Yao,et al.  Synthesis, Structure, DNA‐Binding Properties, and Cytotoxicity of Ruthenium(II) Polypyridyl Complexes , 2010, Chemistry & biodiversity.

[4]  Wen-jie Zheng,et al.  Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. , 2010, Inorganic chemistry.

[5]  Yunjun Liu,et al.  In vitro cytotoxicity, apoptosis, DNA-binding, and antioxidant activity studies of ruthenium (II) complexes. , 2010, DNA and cell biology.

[6]  Jun-hua Yao,et al.  2-(3,5-Dibromo-4-hydroxyphenyl)imidazo[4,5-f][1,10]phenanthrolinoruthenium(II) complexes: synthesis, characterization, cytotoxicity, apoptosis, DNA-binding and antioxidant activity , 2010, BioMetals.

[7]  Yunjun Liu,et al.  Synthesis, DNA-binding, photocleavage, cytotoxicity and antioxidant activity of ruthenium (II) polypyridyl complexes. , 2010, European journal of medicinal chemistry.

[8]  B. Nair,et al.  Synthesis, characterization and DNA binding studies of new ruthenium(II)bisterpyridine complexes. , 2010, European journal of medicinal chemistry.

[9]  L. Tan,et al.  In vitro study on DNA binding of ruthenium(II) complexes with polypyridyl ligands. , 2009, DNA and cell biology.

[10]  R. Parthasarathi,et al.  Synthesis and DNA-binding studies of two ruthenium(II) complexes of an intercalating ligand. , 2009, European journal of medicinal chemistry.

[11]  W. Berger,et al.  KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2009 .

[12]  Tianfeng Chen,et al.  Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. , 2008, Journal of agricultural and food chemistry.

[13]  Y. Wong,et al.  Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation , 2008, Cellular and Molecular Life Sciences.

[14]  Ingo Ott,et al.  Cellular Uptake, Cytotoxicity, and Metabolic Profiling of Human Cancer Cells Treated with Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(NN)]Cl2 with NN=bpy, phen, dpq, dppz, and dppn , 2008, ChemMedChem.

[15]  S. Balasubramanian,et al.  Synthesis, characterization and electrochemistry of 4'-functionalized 2,2':6',2''-terpyridine ruthenium(II) complexes and their biological activity. , 2008, Dalton transactions.

[16]  K. K. Lo,et al.  Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes. , 2008, Inorganic chemistry.

[17]  P. Dyson,et al.  Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy , 2006 .

[18]  M. Jakupec,et al.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.

[19]  P. Sadler,et al.  Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. , 2005, Chemical communications.

[20]  C. Che,et al.  Syntheses of ruthenium(II) quinonediimine complexes of cyclam and characterization of their DNA-binding activities and cytotoxicity. , 2002, Inorganic chemistry.

[21]  E. Steck,et al.  Reactions of Phenanthraquinone and Retenequinone with Aldehydes and Ammonium Acetate in Acetic Acid Solution1 , 2002 .

[22]  G. Sava,et al.  Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma , 2001, Metal-based drugs.

[23]  G. Sava,et al.  Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. , 2000, Pharmacology & toxicology.

[24]  C. Giandomenico,et al.  Current Status of Platinum-Based Antitumor Drugs , 1999 .

[25]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[26]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[27]  N. Grover,et al.  Binding and kinetics studies of oxidation of DNA by oxoruthenium(IV) , 1993 .

[28]  J. Chaires,et al.  Tris(phenanthroline)ruthenium(II) enantiomer interactions with DNA: mode and specificity of binding. , 1993, Biochemistry.

[29]  S. Rokita,et al.  Nickel(III)‐Promoted DNA Cleavage with Ambient Dioxygen , 1993 .

[30]  J. Chaires,et al.  Neither delta- nor lambda-tris(phenanthroline)ruthenium(II) binds to DNA by classical intercalation. , 1992, Biochemistry.

[31]  Shigeyasu Kuroda,et al.  Synthesis and Properties of Diamino-Substituted Dipyrido [3,2-a: 2′,3′-c]phenazine , 1992 .

[32]  Michael T. Carter,et al.  Voltammetric studies of the interaction of metal chelates with DNA. 2. Tris-chelated complexes of cobalt(III) and iron(II) with 1,10-phenanthroline and 2,2'-bipyridine , 1989 .

[33]  R. Oldham,et al.  Utilization of purified human monocytes in the agarose droplet assay for measuring migration inhibitory factors. , 1983, Journal of immunological methods.

[34]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[35]  D. Crothers,et al.  Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. , 1982, Biochemistry.

[36]  B. P. Sullivan,et al.  Mixed phosphine 2,2'-bipyridine complexes of ruthenium , 1978 .

[37]  J. McGhee.  Theoretical calculations of the helix–coil transition of DNA in the presence of large, cooperatively binding ligands , 1976, Biopolymers.

[38]  H. Eisenberg,et al.  Viscosity and sedimentation study of sonicated DNA–proflavine complexes , 1969 .

[39]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[40]  M. Waring,et al.  Complex formation between ethidium bromide and nucleic acids. , 1965, Journal of molecular biology.

[41]  J. Marmur.  A procedure for the isolation of deoxyribonucleic acid from micro-organisms , 1961 .

[42]  S. Rice,et al.  A Further Examination of the Molecular Weight and Size of Desoxypentose Nucleic Acid , 1954 .